Sentences with phrase «with pembrolizumab»

Side effects of any grade of severity were reported in 61 % of patients treated with pembrolizumab compared with 90 % of patients treated with chemotherapy, and more severe side effects that were grade 3, 4, or 5 (the most severe grade) were reported in 15 % and 49 % of patients, respectively.

In a second, late - breaking presentation, Dr Andrea Necchi, attending physician in the Department of Medical Oncology at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, said results from the phase III KEYNOTE - 045 trial showed that treatment with pembrolizumab resulted in longer overall survival with fewer side - effects for patients with previously treated advanced bladder (urothelial) cancer compared with patients given chemotherapy.

A Phase 1b / 2, Open - label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair - Proficient Colorectal Cancer

A Phase 1b / 2 Open - label Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma

«I am treating people today with pembrolizumab alone and seeing some impressive outcomes,» said Dr. Rosalyn Juergens, oncologist and site lead investigator at Hamilton Health Sciences» Juravinski Cancer Centre, and associate professor of oncology at McMaster University.

A Phase Ib / II Trial of Interleukin - 2 in Combination with Pembrolizumab for Patients with Unresectable or Metastatic Melanoma

We are excited to evaluate our technology in combination with pembrolizumab as a potential treatment for lung cancer, and about the promise it may hold for patients,» said Turnstone CEO Sammy Farah, PhD.

This randomized, controlled trial will compare pembrolizumab plus T - VEC with pembrolizumab plus an injected placebo in patients who have not previously received either treatment.

«The significant improvement in overall survival with pembrolizumab was remarkable given that more than 40 % of patients crossed over from the control arm to pembrolizumab after progression of the disease,» said Reck.

But here Butler and colleagues pull three trials together and show that long - lasting responses also occur with pembrolizumab in patients with mucosal melanoma.»

These safety concerns are being evaluated by the FDA with pembrolizumab's manufacturer, Merck.

This combination was well tolerated and highly effective, with a much higher response rate (62 %) than expected with pembrolizumab alone.

Reuters reports that about 30 % of people treated with pembrolizumab experience significant tumor shrinkage.

«The reason KEYNOTE - 024 met its primary endpoint, in contrast with other studies, is probably because the trial only included patients who had PD - L1 expression of at least 50 % and were therefore optimal candidates for treatment with pembrolizumab,» he added.

In one trial, patients treated with pembrolizumab had an overall response rate of 33 %, compared with 12 % for ipilimumab.

This study will evaluate the safety and tolerability of IL - 2 when given in combination with pembrolizumab to patients with advanced melanoma.

Of those treated with pembrolizumab and platinum + pemetrexed, the risk of death was reduced by 51 %, compared to those treated with platinum + pemetrexed alone.

«The data show that treatment with pembrolizumab and chemotherapy together is more effective than chemotherapy alone,» says Gandhi.

A total of 616 patients with untreated, metastatic NSNSCLC without EGFR or ALK alterations, from 118 international sites, were randomly allocated for the trial — 405 patients were treated with both pembrolizumab and platinum + pemetrexed, and 202 received platinum + pemetrexed with a saline placebo.

«All endpoints of efficacy and tolerability favoured treatment with pembrolizumab, suggesting it should become one standard of care for first line treatment of patients with advanced NSCLC and high PD - L1 expression.

The new treatment algorithm should include upfront testing for PD - L1 expression to identify patients who will benefit from first line treatment with pembrolizumab.»

«Sixteen of these patients (19 %) responded to treatment with pembrolizumab, of whom 12 are still alive without their disease progressing and, so far, the longest time some of these patients have continued to be successfully treated is more than 27 months,» he said.

In addition to helping patients live longer, more patients treated with pembrolizumab responded to treatment and for a longer duration than those treated with chemotherapy; the objective response rate — the percentage of patients whose tumours shrank or disappeared — was almost twice as high with pembrolizumab: 21 % compared to 11 % on chemotherapy.

«Patients who were treated with pembrolizumab lived significantly longer than patients who were treated with chemotherapy; the median overall survival was 10.3 months with pembrolizumab and 7.4 months with chemotherapy.

Its first test: CMP - 001 and pembrolizumab in melanoma patients who are failing treatment with pembrolizumab.

OTTAWA, April 26, 2017 / CNW / - Turnstone Biologics Inc. announced today that treatment has been initiated on the first patient in the company's Phase I / II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1 - MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody.

There are two parts to this study: - Phase Ib: To determine the safety and side effects of increasing doses of IL - 2 in combination with pembrolizumab - Phase II: Once the maximum tolerated dose of IL - 2 is determined, additional patients will be treated to determine if it is effective against the cancer.

Studies of PV - 10 with pembrolizumab and of CVA21 with pembrolizumab are also being initiated.